BioSpace News Archive

Job Trends

Discovery Files: A Vision for Blood Cancer Patients

In this episode of Discovery Files, we hear from veteran chemist Andy Souers, Ph.D., distinguished research fellow, AbbVie oncology discovery research, on how his team made a blood cancer discovery.

December 8, 2022
·
1 min read
Drug Development

Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

Exelixis, Inc. (Nasdaq: EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX®).

December 8, 2022
·
15 min read
Biotech Bay

Bristol Myers Squibb Announces Dividend Increase - December 08, 2022

Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents per share on the $.10 par value common stock of the company.

December 8, 2022
·
1 min read
Business

Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors

Certara, Inc. announced that Arsenal Capital Partners, a private equity firm specializing in investing in and building transformational healthcare companies, closed its previously announced $449 million new investment in Certara.

December 8, 2022
·
2 min read
Genetown

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - December 08, 2022

Syndax Pharmaceuticals, Inc. announced that in connection with the hiring, announced on December 5, 2022, of Steve M. Sabus as Chief Commercial Officer, Mr. Sabus received an inducement award to purchase up to 220,000 shares of common stock.

December 8, 2022
·
1 min read
Caeregen Therapeutics Announces FDA Rare Pediatric Disease Designation for Noregen™ in the Treatment Of Familial Exudative Vitreoretinopathy (FEVR)

Caeregen Therapeutics, LLC, a Michigan-based, regenerative medicine therapeutics company, today announced the U.S. Food and Drug Administration (FDA) designated Noregen™ for treatment of Familial Exudative Vitreoretinopathy (FEVR) as a drug for “rare pediatric disease*”.

December 8, 2022
·
5 min read
SK Biopharmaceuticals’ Partner Angelini Pharma Launches Cenobamate in France

SK Biopharmaceuticals announced that its European partner Angelini Pharma, an international pharmaceutical company part of the privately held Italian Angelini Industries, has launched cenobamate in France.

December 8, 2022
·
10 min read